

**Iclusig® (Ponatinib) Prior Authorization Form**

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

**Drug Information**Pharmacy billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_  
Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_**Billing Provider Information**Provider NPI: \_\_\_\_\_ Provider Name: \_\_\_\_\_  
Provider Phone: \_\_\_\_\_ Provider Fax: \_\_\_\_\_**Prescriber Information**Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_  
Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_**Criteria****For Initial Authorization (Initial approval will be for the duration of 6 months):**

1. Please indicate diagnosis and information:

- Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
- A. Induction/consolidation with HyperCVAD? Yes \_\_\_ No \_\_\_
  - B. Maintenance therapy in combination with vincristine and prednisone, with or without methotrexate and mercaptopurine? Yes \_\_\_ No \_\_\_
  - C. Maintenance therapy post-hematopoietic stem cell transplant? Yes \_\_\_ No \_\_\_
  - D. Relapsed/refractory disease either as a single-agent, in combination with chemotherapy not previously given, or in patients with T315I mutations? Yes \_\_\_ No \_\_\_
- Chronic Myeloid Leukemia (CML)
- A. T315I mutation? Yes \_\_\_ No \_\_\_
  - B. Intolerant or resistant to 2 or more tyrosine kinase inhibitors (TKIs)? Yes \_\_\_ No \_\_\_
    - i. If yes, please list the TKIs: \_\_\_\_\_
    - ii. Please provide additional information describing the member's intolerance/resistance: \_\_\_\_\_
  - C. Post-hematopoietic stem cell transplantation in member with prior accelerated or blast phase prior to transplant or who have relapsed? Yes \_\_\_ No \_\_\_
- Other, please provide diagnosis: \_\_\_\_\_

Additional Information: \_\_\_\_\_  
\_\_\_\_\_**For Continued Authorization:**

1. Date of last dose: \_\_\_\_\_
  2. Does member have any evidence of progressive disease while on ponatinib? Yes \_\_\_ No \_\_\_
  3. Has the member experienced adverse drug reactions related to ponatinib therapy? Yes \_\_\_ No \_\_\_
- If yes, please specify adverse reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.***Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned.  
Pharmacy Coverage Guidelines are available at [AetnaBetterHealth.com/Oklahoma](http://AetnaBetterHealth.com/Oklahoma).

**CONFIDENTIALITY NOTICE**

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*